Vaccines · 2020 · 10 citations · 36 references
Life SciencesImmunologyInfectious DiseasesAdaptive ImmunityInnate ImmunityVaccinologyAdaptive Immune ResponsesAntiviral ImmunityImmune Response To VaccinationInnate Immune ActivationInnate Immune ResponseMacrophage BiologyAdaptive Immune Responses To Viral InfectionAnti-viral ImmunityAntiviral Innate SignalingEbola VaccinesImmune Cell ActivationInnate Immunity PathwaysInterferon Response To Viral InfectionVaccine-induced Innate Immunity
Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain mainly unknown. Here, using the clinically available VSV-EBOV vaccine (Ervebo), we show that the cell-intrinsic expression of the interferon-inhibitor Usp18 in CD169+ macrophages is one important factor modulating the anti-Ebola virus immune response. The absence of Usp18 in CD169+ macrophages led to the reduced local replication of VSV-EBOV followed by a diminished innate as well as adaptive immune response. In line, CD169-Cre+/ki x Usp18fl/fl mice showed reduced innate and adaptive immune responses against the VSV wildtype strain and died quickly after infection, suggesting that a lack of Usp18 makes mice more susceptible to the side effects of the VSV vector. In conclusion, our study shows that Usp18 expression in CD169+ macrophages is one important surrogate marker for effective vaccination against VSV-EBOV, and probably other VSV-based vaccines also.
36
Functional Role of Type I and Type II Interferons in Antiviral Defense
Ulrike Müller, Ulrich Steinhoff, Luiz F. L. Reis et al. · Science · 1994 · 2.5K citations · Full text
Seija Lehnardt, Leon J. Massillon, Pamela L. Follett et al. · Proceedings of the National Academy of Sciences · 2003 · 1.1K citations · Full text